Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

July 29, 2020

Study Completion Date

September 9, 2020

Conditions
Vasomotor Symptoms (VMS)
Interventions
DRUG

Q-122

oral capsule of Q-122

DRUG

Placebo

oral capsule of placebo

Trial Locations (18)

1010

Optimal Clinical Trials, Auckland

1023

Auckland City Hospital, Auckland

2000

Women's Health Research Institute of Australia, Sydney

2065

Royal North Shore Hospital, Sydney

3004

School of Public Health and Preventive Medicine, Monash University, Melbourne

3052

The Royal Women's Hospital, Melbourne

3110

P3 Research - Tauranga, Tauranga

4066

ICON Group, Icon Cancer Care Wesley, Brisbane

4130

P3 Research - Hawkes Bay, Havelock North

5000

Royal Adelaide Hospital, Adelaide

6009

Keogh Institute for Medical Research, Perth

8011

Christchurch Clinical Studies Trust Ltd, Christchurch

11794

Stony Brook University, Stony Brook

21287

John Hopkins, Baltimore

30189

North Georgia Clinical Research, Woodstock

46202

Indiana University School of Nursing, Indianapolis

76508

Baylor Scoot & White Medical Center, Temple

02115

Brighams and Women's Hospital, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Que Oncology

INDUSTRY